Assessing health-state utility values in patients with metastatic colorectal cancer: a utility study in the United Kingdom and the Netherlands. Stein, D., Joulain, F., Naoshy, S., Iqbal, U., Muszbek, N., Payne, K. A., Ferry, D., & Goey, S. H. International Journal of Colorectal Disease, 29(10):1203–1210, October, 2014. doi abstract bibtex PURPOSE: This study aimed to elicit EuroQol Quality of Life 5-Dimensions (EQ-5D) utility values from patients with second-line metastatic colorectal cancer (mCRC) pre- and post-progression. METHODS: A cross-sectional study was conducted in five hospitals in the Netherlands and the UK. Patients with mCRC were eligible if prescribed a second or subsequent line of therapy or best supportive care (BSC), received prior oxaliplatin in first-line therapy, and had Eastern Cooperative Oncology Group (ECOG) performance status scores of 0-2 at second-line initiation. Patients completed the EuroQol Quality of Life 5-Dimensions 3-levels (EQ-5D-3L) questionnaire and were categorized as pre- or post-progression. Chart data including patient demographics, clinical history, prior/current treatments and serious adverse events (SAEs) were collected. Mean utilities were estimated; uni- and multivariate analyses were conducted. RESULTS: Seventy-five patients were enrolled; 42 were pre-progression defined as second line or third line following an AE on second line and 33 were post-progression defined as third or subsequent therapy lines or BSC. Patient/disease characteristics and number of SAEs were similar between cohorts. Mean utility scores were 0.741 (SD = 0.230) and 0.731 (SD = 0.292) for pre- and post-progression cohorts, respectively. Compared to pre-progression, more patients reported increased anxiety/depression (36 vs. 12 %) and fewer problems with daily activities (64 vs. 38 %) post-progression. More patients pre-progression were on active treatment at enrolment (83 vs. 42 %) compared to post-progression. CONCLUSIONS: This is the first real-world study to collect utilities for patients with second-line mCRC pre- and post-disease progression. Utility values were similar pre- and post-progression. To further explore the effect of radiological progression on utilities, longitudinal research is required that includes patients in palliative care centres.
@article{stein_assessing_2014-1,
title = {Assessing health-state utility values in patients with metastatic colorectal cancer: a utility study in the {United} {Kingdom} and the {Netherlands}},
volume = {29},
issn = {1432-1262},
shorttitle = {Assessing health-state utility values in patients with metastatic colorectal cancer},
doi = {10.1007/s00384-014-1980-1},
abstract = {PURPOSE: This study aimed to elicit EuroQol Quality of Life 5-Dimensions (EQ-5D) utility values from patients with second-line metastatic colorectal cancer (mCRC) pre- and post-progression. METHODS: A cross-sectional study was conducted in five hospitals in the Netherlands and the UK. Patients with mCRC were eligible if prescribed a second or subsequent line of therapy or best supportive care (BSC), received prior oxaliplatin in first-line therapy, and had Eastern Cooperative Oncology Group (ECOG) performance status scores of 0-2 at second-line initiation. Patients completed the EuroQol Quality of Life 5-Dimensions 3-levels (EQ-5D-3L) questionnaire and were categorized as pre- or post-progression. Chart data including patient demographics, clinical history, prior/current treatments and serious adverse events (SAEs) were collected. Mean utilities were estimated; uni- and multivariate analyses were conducted. RESULTS: Seventy-five patients were enrolled; 42 were pre-progression defined as second line or third line following an AE on second line and 33 were post-progression defined as third or subsequent therapy lines or BSC. Patient/disease characteristics and number of SAEs were similar between cohorts. Mean utility scores were 0.741 (SD = 0.230) and 0.731 (SD = 0.292) for pre- and post-progression cohorts, respectively. Compared to pre-progression, more patients reported increased anxiety/depression (36 vs. 12 \%) and fewer problems with daily activities (64 vs. 38 \%) post-progression. More patients pre-progression were on active treatment at enrolment (83 vs. 42 \%) compared to post-progression. CONCLUSIONS: This is the first real-world study to collect utilities for patients with second-line mCRC pre- and post-disease progression. Utility values were similar pre- and post-progression. To further explore the effect of radiological progression on utilities, longitudinal research is required that includes patients in palliative care centres.},
language = {eng},
number = {10},
journal = {International Journal of Colorectal Disease},
author = {Stein, D. and Joulain, F. and Naoshy, S. and Iqbal, U. and Muszbek, N. and Payne, K. A. and Ferry, D. and Goey, S. H.},
month = oct,
year = {2014},
pmid = {25080148},
keywords = {Activities of Daily Living, Antineoplastic Agents, Anxiety, Colorectal Neoplasms, Cross-Sectional Studies, Depression, Disease Progression, Female, Humans, Male, Middle Aged, Netherlands, oncology, Organoplatinum Compounds, Oxaliplatin, Pain, Palliative Care, Quality of Life, Surveys and Questionnaires, United Kingdom},
pages = {1203--1210},
}
Downloads: 0
{"_id":"ir3CZd8aKZNh6iKjw","bibbaseid":"stein-joulain-naoshy-iqbal-muszbek-payne-ferry-goey-assessinghealthstateutilityvaluesinpatientswithmetastaticcolorectalcancerautilitystudyintheunitedkingdomandthenetherlands-2014","authorIDs":[],"author_short":["Stein, D.","Joulain, F.","Naoshy, S.","Iqbal, U.","Muszbek, N.","Payne, K. A.","Ferry, D.","Goey, S. H."],"bibdata":{"bibtype":"article","type":"article","title":"Assessing health-state utility values in patients with metastatic colorectal cancer: a utility study in the United Kingdom and the Netherlands","volume":"29","issn":"1432-1262","shorttitle":"Assessing health-state utility values in patients with metastatic colorectal cancer","doi":"10.1007/s00384-014-1980-1","abstract":"PURPOSE: This study aimed to elicit EuroQol Quality of Life 5-Dimensions (EQ-5D) utility values from patients with second-line metastatic colorectal cancer (mCRC) pre- and post-progression. METHODS: A cross-sectional study was conducted in five hospitals in the Netherlands and the UK. Patients with mCRC were eligible if prescribed a second or subsequent line of therapy or best supportive care (BSC), received prior oxaliplatin in first-line therapy, and had Eastern Cooperative Oncology Group (ECOG) performance status scores of 0-2 at second-line initiation. Patients completed the EuroQol Quality of Life 5-Dimensions 3-levels (EQ-5D-3L) questionnaire and were categorized as pre- or post-progression. Chart data including patient demographics, clinical history, prior/current treatments and serious adverse events (SAEs) were collected. Mean utilities were estimated; uni- and multivariate analyses were conducted. RESULTS: Seventy-five patients were enrolled; 42 were pre-progression defined as second line or third line following an AE on second line and 33 were post-progression defined as third or subsequent therapy lines or BSC. Patient/disease characteristics and number of SAEs were similar between cohorts. Mean utility scores were 0.741 (SD = 0.230) and 0.731 (SD = 0.292) for pre- and post-progression cohorts, respectively. Compared to pre-progression, more patients reported increased anxiety/depression (36 vs. 12 %) and fewer problems with daily activities (64 vs. 38 %) post-progression. More patients pre-progression were on active treatment at enrolment (83 vs. 42 %) compared to post-progression. CONCLUSIONS: This is the first real-world study to collect utilities for patients with second-line mCRC pre- and post-disease progression. Utility values were similar pre- and post-progression. To further explore the effect of radiological progression on utilities, longitudinal research is required that includes patients in palliative care centres.","language":"eng","number":"10","journal":"International Journal of Colorectal Disease","author":[{"propositions":[],"lastnames":["Stein"],"firstnames":["D."],"suffixes":[]},{"propositions":[],"lastnames":["Joulain"],"firstnames":["F."],"suffixes":[]},{"propositions":[],"lastnames":["Naoshy"],"firstnames":["S."],"suffixes":[]},{"propositions":[],"lastnames":["Iqbal"],"firstnames":["U."],"suffixes":[]},{"propositions":[],"lastnames":["Muszbek"],"firstnames":["N."],"suffixes":[]},{"propositions":[],"lastnames":["Payne"],"firstnames":["K.","A."],"suffixes":[]},{"propositions":[],"lastnames":["Ferry"],"firstnames":["D."],"suffixes":[]},{"propositions":[],"lastnames":["Goey"],"firstnames":["S.","H."],"suffixes":[]}],"month":"October","year":"2014","pmid":"25080148","keywords":"Activities of Daily Living, Antineoplastic Agents, Anxiety, Colorectal Neoplasms, Cross-Sectional Studies, Depression, Disease Progression, Female, Humans, Male, Middle Aged, Netherlands, oncology, Organoplatinum Compounds, Oxaliplatin, Pain, Palliative Care, Quality of Life, Surveys and Questionnaires, United Kingdom","pages":"1203–1210","bibtex":"@article{stein_assessing_2014-1,\n\ttitle = {Assessing health-state utility values in patients with metastatic colorectal cancer: a utility study in the {United} {Kingdom} and the {Netherlands}},\n\tvolume = {29},\n\tissn = {1432-1262},\n\tshorttitle = {Assessing health-state utility values in patients with metastatic colorectal cancer},\n\tdoi = {10.1007/s00384-014-1980-1},\n\tabstract = {PURPOSE: This study aimed to elicit EuroQol Quality of Life 5-Dimensions (EQ-5D) utility values from patients with second-line metastatic colorectal cancer (mCRC) pre- and post-progression. METHODS: A cross-sectional study was conducted in five hospitals in the Netherlands and the UK. Patients with mCRC were eligible if prescribed a second or subsequent line of therapy or best supportive care (BSC), received prior oxaliplatin in first-line therapy, and had Eastern Cooperative Oncology Group (ECOG) performance status scores of 0-2 at second-line initiation. Patients completed the EuroQol Quality of Life 5-Dimensions 3-levels (EQ-5D-3L) questionnaire and were categorized as pre- or post-progression. Chart data including patient demographics, clinical history, prior/current treatments and serious adverse events (SAEs) were collected. Mean utilities were estimated; uni- and multivariate analyses were conducted. RESULTS: Seventy-five patients were enrolled; 42 were pre-progression defined as second line or third line following an AE on second line and 33 were post-progression defined as third or subsequent therapy lines or BSC. Patient/disease characteristics and number of SAEs were similar between cohorts. Mean utility scores were 0.741 (SD = 0.230) and 0.731 (SD = 0.292) for pre- and post-progression cohorts, respectively. Compared to pre-progression, more patients reported increased anxiety/depression (36 vs. 12 \\%) and fewer problems with daily activities (64 vs. 38 \\%) post-progression. More patients pre-progression were on active treatment at enrolment (83 vs. 42 \\%) compared to post-progression. CONCLUSIONS: This is the first real-world study to collect utilities for patients with second-line mCRC pre- and post-disease progression. Utility values were similar pre- and post-progression. To further explore the effect of radiological progression on utilities, longitudinal research is required that includes patients in palliative care centres.},\n\tlanguage = {eng},\n\tnumber = {10},\n\tjournal = {International Journal of Colorectal Disease},\n\tauthor = {Stein, D. and Joulain, F. and Naoshy, S. and Iqbal, U. and Muszbek, N. and Payne, K. A. and Ferry, D. and Goey, S. H.},\n\tmonth = oct,\n\tyear = {2014},\n\tpmid = {25080148},\n\tkeywords = {Activities of Daily Living, Antineoplastic Agents, Anxiety, Colorectal Neoplasms, Cross-Sectional Studies, Depression, Disease Progression, Female, Humans, Male, Middle Aged, Netherlands, oncology, Organoplatinum Compounds, Oxaliplatin, Pain, Palliative Care, Quality of Life, Surveys and Questionnaires, United Kingdom},\n\tpages = {1203--1210},\n}\n\n","author_short":["Stein, D.","Joulain, F.","Naoshy, S.","Iqbal, U.","Muszbek, N.","Payne, K. A.","Ferry, D.","Goey, S. H."],"bibbaseid":"stein-joulain-naoshy-iqbal-muszbek-payne-ferry-goey-assessinghealthstateutilityvaluesinpatientswithmetastaticcolorectalcancerautilitystudyintheunitedkingdomandthenetherlands-2014","role":"author","urls":{},"keyword":["Activities of Daily Living","Antineoplastic Agents","Anxiety","Colorectal Neoplasms","Cross-Sectional Studies","Depression","Disease Progression","Female","Humans","Male","Middle Aged","Netherlands","oncology","Organoplatinum Compounds","Oxaliplatin","Pain","Palliative Care","Quality of Life","Surveys and Questionnaires","United Kingdom"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://bibbase.org/f/FfNE7kWA6pCvwcJZF/myPubs.bib","creationDate":"2019-10-29T16:07:38.341Z","downloads":0,"keywords":["activities of daily living","antineoplastic agents","anxiety","colorectal neoplasms","cross-sectional studies","depression","disease progression","female","humans","male","middle aged","netherlands","oncology","organoplatinum compounds","oxaliplatin","pain","palliative care","quality of life","surveys and questionnaires","united kingdom"],"search_terms":["assessing","health","state","utility","values","patients","metastatic","colorectal","cancer","utility","study","united","kingdom","netherlands","stein","joulain","naoshy","iqbal","muszbek","payne","ferry","goey"],"title":"Assessing health-state utility values in patients with metastatic colorectal cancer: a utility study in the United Kingdom and the Netherlands","year":2014,"dataSources":["sMi9tjFo5gDXmBZje","ZaHtWavQhcwZqKLNF","iRRNaRs6FkffgErta","zeMwFvgpdRkYAkfoD","v8uQmZsBpiqycmskv"]}